Literature DB >> 16377669

Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers.

Gabriela Grunder1, Yvonne Zysset-Aschmann, Florence Vollenweider, Thomas Maier, Stephan Krähenbühl, Juergen Drewe.   

Abstract

Several antibiotics show significant pharmacokinetic interactions when they are given orally concomitantly with antacids. The objective of this study was to evaluate the effects of antacid (containing magnesium) on the pharmacokinetics of linezolid. A single dose of 600 mg linezolid was given orally alone and 10 min after administration of the antacid Maalox 70mVal, which contains 600 mg magnesium hydroxide and 900 mg aluminum hydroxide, to nine healthy males and nine healthy females in a crossover and randomized study. Linezolid plasma concentrations were determined by high-performance liquid chromatography, and pharmacokinetic parameters were calculated for both treatments. Coadministration with antacids did not change the pharmacokinetics of linezolid. The ratios (90% confidence intervals) of the individual values of the area under the concentration-time curve and the maximum concentration in plasma (C(max)) (linezolid plus antacid versus linezolid alone) were 1.01 (0.99 to 1.02) and 0.99 (0.96 to 1.02), respectively. Likewise, no significant difference in any of the other pharmacokinetic parameters was observed between the treatment groups (the time to C(max), lag time, volume of distribution [V/F], and clearance [CL/F]). However, a significant sex difference was observed for AUC, C(max), V/F, and CL/F; and these differences could be almost completely explained by the differences in body weight between males and females. No clinically relevant adverse effects were detected under either condition. The coadministration of antacids had no effect on the pharmacokinetics of linezolid. This demonstrates that the oral absorption of linezolid was not affected by the presence of antacids containing magnesium hydroxide and aluminum hydroxide. Antacids can be safely administered together with linezolid.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16377669      PMCID: PMC1346802          DOI: 10.1128/AAC.50.1.68-72.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers.

Authors:  A Allen; M Vousden; A Porter; A Lewis
Journal:  Chemotherapy       Date:  1999 Nov-Dec       Impact factor: 2.544

2.  Age and sex effects on the pharmacokinetics of linezolid.

Authors:  T Lasher Sisson; G L Jungbluth; N K Hopkins
Journal:  Eur J Clin Pharmacol       Date:  2002-01       Impact factor: 2.953

3.  Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers.

Authors:  Olaf Burkhardt; Klaus Borner; Nicolas von der Höh; Peter Köppe; Mathias Wilhelm Pletz; Carl Erik Nord; Hartmut Lode
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

4.  Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans.

Authors:  J M Jaffe; R I Poust; S L Feld; J L Colaizzi
Journal:  J Pharm Sci       Date:  1974-08       Impact factor: 3.534

5.  Drug diffusion and bioavailability: tetracycline metallic chelation.

Authors:  T F Chin; J L Lach
Journal:  Am J Hosp Pharm       Date:  1975-06

6.  Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia.

Authors:  P F Smith; M C Birmingham; G A Noskin; A K Meagher; A Forrest; C R Rayner; J J Schentag
Journal:  Ann Oncol       Date:  2003-05       Impact factor: 32.976

7.  Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers.

Authors:  A Allen; M Vousden; A Lewis
Journal:  Chemotherapy       Date:  1999 Nov-Dec       Impact factor: 2.544

8.  A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum.

Authors:  C M Tobin; J Sunderland; L O White; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

9.  Linezolid-induced bradycardia: a case report.

Authors:  Alfredo Tartarone; Giuseppina Gallucci; Giovanni Iodice; Giampiero Romano; Mariarosa Coccaro; Maria Luigia Vigliotti; Giuseppe Mele; Rosella Matera; Nicola Di Renzo
Journal:  Int J Antimicrob Agents       Date:  2004-04       Impact factor: 5.283

10.  Mechanisms for linezolid-induced anemia and thrombocytopenia.

Authors:  Wendy B Bernstein; Richard F Trotta; James T Rector; Jeffery A Tjaden; Anthony J Barile
Journal:  Ann Pharmacother       Date:  2003-04       Impact factor: 3.154

View more
  5 in total

Review 1.  Clinically significant drug interactions with antacids: an update.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

2.  Applicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of Ctrough- over Cmax-Derived Linear Regression Models.

Authors:  Nuggehally R Srinivas; Muzeeb Syed
Journal:  Drugs R D       Date:  2016-03

3.  Clinical update on linezolid in the treatment of Gram-positive bacterial infections.

Authors:  Sally Ager; Kate Gould
Journal:  Infect Drug Resist       Date:  2012-06-25       Impact factor: 4.003

Review 4.  MDR Tuberculosis Treatment.

Authors:  Juan Espinosa-Pereiro; Adrian Sánchez-Montalvá; Maria Luisa Aznar; Maria Espiau
Journal:  Medicina (Kaunas)       Date:  2022-01-26       Impact factor: 2.430

5.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.